06/17/2026 08:42
Forrester Opens Nominations For Its 2026 B2B Awards In EMEA

Forrester (Nasdaq: FORR) today opened nominations for its 2026 B2B Return On Integration Honours and B2B Programmes Of The Year Awards for Europe, the Middle East, and Africa (EMEA). The awards recognize organisations that are driving measurable business impact through customer-obsessed growth strategies. Winners will be honoured at Forrester’s B2B Forum EMEA, taking place in London, 28–29 September 2026. The B2B Return On Integration (ROI) Honours celebrate organisations that have successful...

05/07/2026 11:00
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)

In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovatio...

AFP photographer Said Khatib wins the Mingote Prize in Spain

Said Khatib was awarded the prestigious Mingote Prize on Thursday in Madrid, in the presence of King Felipe VI of Spain and Queen Letizia, for a photograph taken in the Gaza Strip in October 2023.

Said Khatib was awarded the prestigious Mingote Prize on Thursday in Madrid, in the presence of King Felipe VI of Spain and Queen Letizia, for a photograph taken in the Gaza Strip in October 2023.
05/07/2026 12:00
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitig...